Literature DB >> 3999311

Long-term surveillance for adverse effects of antihypertensive drugs.

J D Curb, N O Borhani, T P Blaszkowski, N Zimbaldi, S Fotiu, W Williams.   

Abstract

The large number of participants (5,485 patients) in the Hypertension Detection and Follow-Up Program, Stepped Care, form the largest group to date on which detailed surveillance of long-term antihypertensive therapy and drug side effects has been reported. Over a five-year period, among all hypertensive persons (mild, moderate, and severe combined) who were not taking antihypertensive medications at the beginning of the study and who attended the clinic at least once during the five-year trial, a total of 9.3% had definite or probable side effects severe enough to cause discontinuation of the drug treatment in question. An additional 23.4% had drug treatment discontinued due to possible side effects. Within the mild, moderate, and severe hypertension categories, 8.6%, 11%, and 12%, respectively, had definite or probable side effects. The incidence of side effects declined over the five years in all race-sex groups. Five-year incidence of total side effects was 29.8% in those aged 60 to 69 years at entry and 38.0%, 36.8%, and 34.1%, respectively, in those aged 50 to 59, 40 to 49, and 30 to 39 years. Sexually related side effects required discontinuation of treatment in 8.3% of male participants. However, less than 1% of active participants required hospitalization for side effects. No death that could be attributed to side effects was detected. Thus, the Hypertension Detection and Follow-up Program data, which have previously demonstrated the beneficial effects of antihypertensive therapy, confirm the relative safety of such therapy.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3999311

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  34 in total

1.  A comparison of verapamil and nifedipine on quality of life.

Authors:  A Palmer; A Fletcher; G Hamilton; S Muriss; C Bulpitt
Journal:  Br J Clin Pharmacol       Date:  1990-09       Impact factor: 4.335

Review 2.  What do you do when the blood pressure is up? An approach to the known hypertensive who has an elevated blood pressure.

Authors:  R L Schiff; M H Cohen; A Balson
Journal:  J Gen Intern Med       Date:  1991 Jan-Feb       Impact factor: 5.128

Review 3.  Prevention. How much harm? How much benefit? 2. Ten potential pitfalls in determining the clinical significance of benefits.

Authors:  K G Marshall
Journal:  CMAJ       Date:  1996-06-15       Impact factor: 8.262

4.  Documentation of an instrument for assessment of subjective CNS-related symptoms during cardiovascular pharmacotherapy.

Authors:  C Dahlöf; E Dimenäs; B Olofsson
Journal:  Cardiovasc Drugs Ther       Date:  1989-12       Impact factor: 3.727

5.  [Effects of endovascular therapy for renal artery stenosis on blood pressure and renal function: retrospective analysis of an unselected patient collective from 1994 to 2007].

Authors:  K B Krug; O Rehder; H Bovenschulte; H Schwabe; V Burst; U Engelmann; R Thul; S Mönig; M Hellmich
Journal:  Urologe A       Date:  2012-11       Impact factor: 0.639

6.  Therapeutic choices for the older hypertensive patient.

Authors:  W B Applegate
Journal:  J Natl Med Assoc       Date:  1989-04       Impact factor: 1.798

7.  Postmarketing surveillance of adverse drug reactions: problems and solutions.

Authors:  F M Lortie
Journal:  CMAJ       Date:  1986-07-01       Impact factor: 8.262

Review 8.  Effect of antihypertensive agents on quality of life in the elderly.

Authors:  Roberto Fogari; Annalisa Zoppi
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

Review 9.  The elderly patient. A special case for diuretic therapy.

Authors:  D E Hyams
Journal:  Drugs       Date:  1986       Impact factor: 9.546

10.  Analysis of pharmacotherapy of hypertension in out-patients.

Authors:  J Vlcek; M Tesarová; Z Fendrich
Journal:  Pharm World Sci       Date:  1995-05-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.